Published online before print
February 14, 2007, 10.1183/09031936.00146306
Eur Respir J 2007; 29:906-913
Copyright ©ERS Journals Ltd 2007
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
R. Siva,
R. H. Green,
C. E. Brightling,
M. Shelley,
B. Hargadon,
S. McKenna,
W. Monteiro,
M. Berry,
D. Parker,
A. J. Wardlaw and
I. D. Pavord
Institute for Lung Health, Dept of Respiratory Medicine and Thoracic Surgery, Glenfield Hospital, Leicester, UK.
CORRESPONDENCE: I. D. Pavord, Institute for Lung Health, Glenfield Hospital, Groby Road, Leicester, LE3 9PQ, UK. Fax: 44 1162367768. E-mail: ian.pavord{at}uhl-tr.nhs.uk
Keywords: Airway inflammation, chronic obstructive pulmonary disease, corticosteroids, eosinophils, exacerbations
Received: November 8, 2006
Accepted January 21, 2007
Evidence suggests that eosinophilic airway inflammation is important in the pathogenesis of severe chronic obstructive pulmonary disease (COPD) exacerbations. The present authors tested the hypothesis that a management strategy that aims to reduce sputum eosinophil counts is associated with a reduction in exacerbations of COPD.
A total of 82 patients with COPD were randomised into two groups. One group was treated according to traditional guidelines (British Thoracic Society (BTS) group) and the other (sputum group) was treated with the additional aim of minimising eosinophilic airway inflammation, assessed using the induced sputum eosinophil count. The primary outcome was exacerbations, which were categorised as mild, moderate or severe.
The frequency of severe exacerbations per patient per year was 0.5 and 0.2 in the BTS and sputum groups, respectively (mean reduction 62%). The majority of this benefit was confined to patients with eosinophilic airway inflammation. There was no difference in the frequency of mild and moderate exacerbations. The average daily dose of inhaled or oral corticosteroids during the trial did not differ between the groups. Out of 42 patients in the sputum group, 17 required regular oral corticosteroids to minimise eosinophilic airway inflammation.
A management strategy that aims to minimise eosinophilic airway inflammation, as well as symptoms, is associated with a reduction in severe exacerbations of chronic obstructive pulmonary disease.
This article has been cited by other articles:

|
 |

|
 |
 
J. F. Dummer, M. J. Epton, J. O. Cowan, J. M. Cook, R. Condliffe, C. E. Landhuis, A. D. Smith, and D. R. Taylor
Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease Using Exhaled Nitric Oxide
Am. J. Respir. Crit. Care Med.,
November 1, 2009;
180(9):
846 - 852.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Haldar, C. E. Brightling, B. Hargadon, S. Gupta, W. Monteiro, A. Sousa, R. P. Marshall, P. Bradding, R. H. Green, A. J. Wardlaw, et al.
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
N. Engl. J. Med.,
March 5, 2009;
360(10):
973 - 984.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D R Taylor and I D Pavord
Biomarkers in the assessment and management of airways diseases
Postgrad. Med. J.,
December 1, 2008;
84(998):
628 - 634.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Saglani and A. Bush
Asthma, Atopy, and Airway Inflammation: What Does It Mean in Practice?
Am. J. Respir. Crit. Care Med.,
September 1, 2008;
178(5):
437 - 438.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Todd, R. A. McIvor, S. O. Pugsley, and G. Cox
Approach to chronic obstructive pulmonary disease in primary care
Can Fam Physician,
May 1, 2008;
54(5):
706 - 711.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. MacNee
Update in Chronic Obstructive Pulmonary Disease 2007
Am. J. Respir. Crit. Care Med.,
April 15, 2008;
177(8):
820 - 829.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Maestrelli
Same role and same treatment for airway eosinophilia in asthma and COPD?
Eur. Respir. J.,
May 1, 2007;
29(5):
831 - 833.
[Full Text]
[PDF]
|
 |
|
Copyright © 2007 by the European Respiratory Society.
|